These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 14700343)

  • 21. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. I. Single-dose study.
    Acocella G; Nonis A; Gialdroni-Grassi G; Grassi C
    Am Rev Respir Dis; 1988 Oct; 138(4):882-5. PubMed ID: 3202464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study].
    Yoshiyama T; Ogata H; Ito K; Aono A; Wada M
    Kekkaku; 2007 Feb; 82(2):95-101. PubMed ID: 17373318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of pyrazinamide on rifampicin kinetics in patients with tuberculosis.
    Jain A; Mehta VL; Kulshrestha S
    Tuber Lung Dis; 1993 Apr; 74(2):87-90. PubMed ID: 8324212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
    Int J Tuberc Lung Dis; 1997 Dec; 1(6):509-17. PubMed ID: 9487448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis.
    Langdon G; Wilkins JJ; Smith PJ; McIlleron H
    Int J Tuberc Lung Dis; 2004 Jul; 8(7):862-7. PubMed ID: 15260278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of rifampicin and pyrazinamide on isoniazid pharmacokinetics in rats.
    Baldan HM; De Rosa HJ; Brunetti IL; Ximenes VF; Machado RG
    Biopharm Drug Dispos; 2007 Nov; 28(8):409-13. PubMed ID: 17828712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy.
    Acocella G; Luisetti M; Grassi GG; Peona V; Pozzi E; Grassi C
    Monaldi Arch Chest Dis; 1993; 48(3):205-9. PubMed ID: 8369784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol.
    Malone RS; Fish DN; Spiegel DM; Childs JM; Peloquin CA
    Am J Respir Crit Care Med; 1999 May; 159(5 Pt 1):1580-4. PubMed ID: 10228130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of bioequivalence of isoniazid and pyrazinamide in three and four drugs fixed dose combinations using WHO simplified protocol.
    Panchagnula R; Sancheti P; Rungta S; Agrawal S; Kaul CL
    Pharmacol Res; 2003 Oct; 48(4):383-7. PubMed ID: 12902209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products.
    Singh S; Mohan B
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):298-303. PubMed ID: 12661847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The colorimetric analysis of anti-tuberculosis fixed-dose combination tablets and capsules.
    Ellard GA
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S343-6; discussion S351-2. PubMed ID: 10593715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clearance of theophylline is increased during the initial period of tuberculosis treatment.
    Ahn HC; Lee YC
    Int J Tuberc Lung Dis; 2003 Jun; 7(6):587-91. PubMed ID: 12797703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
    Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R
    Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioequivalence of rifampicin when administered as a fixed-dose combined formulation of four drugs versus separate formulations.
    Panchagnula R; Kaur KJ; Singh I; Kaul CL
    Methods Find Exp Clin Pharmacol; 2000 Nov; 22(9):689-94. PubMed ID: 11294011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Results of short-term tuberculosis therapy with isoniazid, rifampicin and pyrazinamide].
    Brändli O; Dreher D; Morger D
    Schweiz Med Wochenschr; 1993 Jun; 123(25):1300-6. PubMed ID: 8341998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso.
    Saleri N; Dembélé SM; Villani P; Carvalho AC; Cusato M; Bonkoungou V; Nacanabo R; Kouanda S; Comelli M; Regazzi M; Matteelli A
    J Antimicrob Chemother; 2012 Feb; 67(2):469-72. PubMed ID: 22028201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi.
    van Oosterhout JJ; Dzinjalamala FK; Dimba A; Waterhouse D; Davies G; Zijlstra EE; Molyneux ME; Molyneux EM; Ward S
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6175-80. PubMed ID: 26248378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protein Binding of First-Line Antituberculosis Drugs.
    Alghamdi WA; Al-Shaer MH; Peloquin CA
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29735566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.